DEFA14A: Monogram Amends Merger Deal with Zimmer Biomet

Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc. amended their merger agreement, specifically modifying the definition of "Permitted Transfer" in the CVR Agreement following an SEC comment.

Summary

• Monogram Technologies Inc. (MGRM) and Zimmer Biomet Holdings, Inc. (Parent) executed a First Amendment to their Agreement and Plan of Merger on August 27, 2025.
• The amendment was made in response to a verbal comment from the U.S. Securities and Exchange Commission (SEC).
• The specific change involves the deletion of Clause (g) from the definition of "Permitted Transfer" within the Contingent Value Rights (CVR) Agreement, which is Exhibit B to the original Merger Agreement.
• The original Merger Agreement, dated July 11, 2025, outlines the merger of Honey Badger Merger Sub, Inc. (a wholly-owned subsidiary of Parent) into Monogram, making Monogram a wholly-owned subsidiary of Parent.
• All other terms and provisions of the original Merger Agreement remain unchanged and in full force and effect.

Sentiment

Score: 7

Explanation: The filing indicates progress on a previously announced merger, addressing a regulatory comment. While the specific impact of the CVR amendment is unclear, the overall transaction appears to be moving forward, which is generally positive for the company's strategic direction. The regulatory engagement is a normal part of the process.

Positives

• The amendment addresses a verbal comment from the SEC, indicating proactive engagement with regulatory bodies and potentially smoothing the path for merger approval.
• The core merger agreement remains in full force and effect, suggesting the overall transaction is proceeding as planned.

Negatives

• The need for an amendment, even a minor one, due to an SEC comment could indicate initial oversight or a point of contention that required clarification.
• The specific impact of deleting Clause (g) from "Permitted Transfer" in the CVR Agreement is not detailed, making it difficult to assess potential implications for CVR holders without further context.

Risks

• Regulatory scrutiny: The SEC's verbal comment and subsequent amendment highlight ongoing regulatory review of the merger, which could lead to further requests or delays.
• Uncertainty regarding CVRs: The change to "Permitted Transfer" in the CVR Agreement could affect the transferability or value of contingent value rights for Monogram shareholders, depending on the original clause's content.
• Merger completion risk: While the amendment is minor, any regulatory interaction carries a residual risk of impacting the merger timeline or terms.

Future Outlook

The amendment indicates that the merger process between Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc. is progressing, with regulatory feedback being addressed to facilitate the transaction's completion. The core terms of Monogram becoming a wholly-owned subsidiary of Zimmer Biomet remain in place.

Management Comments

• Monogram Technologies Inc. duly caused this report to be signed on its behalf by Benjamin Sexson, Chief Executive Officer.
• Zimmer Biomet Holdings, Inc. duly executed this Amendment by Chad F. Phipps, Senior Vice President, General Counsel and Secretary.
• Monogram Technologies Inc. duly executed this Amendment by Noel Knape, Chief Financial Officer.

Industry Context

This amendment is a standard procedural step in large corporate mergers, especially those involving publicly traded companies, where regulatory bodies like the SEC review transaction documents for compliance and clarity. Such adjustments are common and typically do not signal a fundamental issue with the strategic rationale of the merger, which aims to integrate Monogram Technologies into Zimmer Biomet's operations, likely within the medical technology or orthopedic device sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The amendment clarifies a term in the CVR Agreement, which could impact the value or transferability of contingent value rights received by Monogram shareholders in the merger. The overall merger is proceeding, which is a significant event for shareholders.
• Regulatory Authorities: The SEC's verbal comment was addressed, demonstrating compliance and cooperation with regulatory oversight.

Next Steps

• Completion of the merger of Honey Badger Merger Sub, Inc. into Monogram Technologies Inc.
• Monogram Technologies Inc. becoming a wholly-owned subsidiary of Zimmer Biomet Holdings, Inc.
• Further regulatory approvals or conditions as required for the merger.

Key Dates

Recommendation

The filing details a minor amendment to a previously announced merger agreement, addressing a regulatory comment. While the specific impact of the CVR 'Permitted Transfer' definition change is not fully elaborated, the core merger transaction appears to be on track. Investors holding Monogram stock should continue to hold, awaiting the completion of the merger and further details on the CVRs. The amendment itself does not provide new fundamental information to warrant a change in investment thesis, but rather confirms ongoing regulatory process.

Keywords

Monogram Technologies, Zimmer Biomet, Merger Agreement, SEC Filing, MGRM, Acquisition, Contingent Value Rights, CVR, Regulatory Compliance, Corporate Governance